medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2018; 17 (1)


Recreational Drug and Psychosocial Profile in Chronic Hepatitis C Patients Seeking Antiviral Therapy

George N, Harrell SM, Rhodes KD, Duarte-Rojo A

Idioma: Ingles.
Referencias bibliográficas: 50
Paginas: 76-84
Archivo PDF: 236.60 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. MMWR Morb Mortal Wkly Rep. Testing for HCV Infection: An Update of Guidance for Clinicians and Laboratorians. Centres For Disease Control And Prevention (CDC) 2013; 10: 362-5.

  2. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, et al. Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis. Clin Infect Dis 2013; 57: S80-9.

  3. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.

  4. Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, Hamdounia SB, et al. Emerging Epidemic of Hepatitis C Virus Infections Among Young Nonurban Persons Who Inject Drugs in the United States, 2006-2012. Clin Infect Dis 2014; 59: 1411-9.

  5. Suk KT, Mederacke I, Gwak GY, Cho SW, Adeyemi A, Friedman R, Schwabe RF. Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis. Gut 2016; 65: 1721-32.

  6. Hézode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M, Medkour F, et al. Daily Canna bis Use: A Novel Risk Factor of Steatosis Severity in Patients With Chronic Hepatitis C. Gastroenterology 2008; 134: 432-9.

  7. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-6.

  8. Khan KN, Yatsuhashi H. Effect of Alcohol Consumption on the Progression of Hepatitis C Virus Infection and Risk of Hepatocellular Carcinoma in Japanese Patients. Alcohol Alcohol 2000; 35: 286-95.

  9. Ross HE, Glaser FB, Germanson T. The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Arch Gen Psychiatry 1988; 45: 1023-31.

  10. Khantzian EJ, Treece C. DSM-III psychiatric diagnosis of narcotic addicts. Recent findings. Arch Gen Psychiatry 1985; 42: 1067-71.

  11. Rounsaville BJ, Weissman MM, Kleber H, Wilber C. Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry 1982; 39: 161-8.

  12. Weissman MM, Myers JK, Harding PS. Prevalence and psychiatric heterogeneity of alcoholism in a United States urban community. J Stud Alcohol 1980; 41: 672-81.

  13. Comorbid Drug Abuse and Mental Illness - comorbid.pdf [Internet]. [cited 2016 Nov 2]. Available from: https://www.apa.org/about/gr/issues/substance-abuse/comorbid.pdf

  14. Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 2016; 43: 1276-92.

  15. Grebely J, Oser M, Taylor LE, Dore GJ. Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV/HIV Coinfection: Action Required at the System, Provider, and Patient Levels. J Infect Dis 2013; 15: S19-25.

  16. Grebely J, Bruggmann P, Treloar C, Byrne J, Rhodes T, Dore GJ. Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. Int J Drug Policy 2015; 26: 893-8.

  17. Edlin BR. Prevention and Treatment of Hepatitis C in Injection Drug Users. Hepatol Baltim Md 2002; 36: S210-9.

  18. Zeremski M, Zibbell JE, Martinez AD, Kritz S, Smith BD, Talal AH. Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol 2013; 19: 7846-51.

  19. Grebely J, Dore G. What Is Killing People with Hepatitis C Virus Infection? Semin Liver Dis 2011; 31: 331-9.

  20. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54: 1137-44.

  21. Alcohol Facts and Statistics | National Institute on Alcohol Abuse and Alcoholism (NIAAA) [Internet]. [cited 2016 Sep 22]. Available from: https: //www.niaaa.nih.gov/alcoholhealth/ overview-alcohol-consumption/alcohol-facts-and-statistics

  22. Skeff KM. Restructuring the patient’s history: enhancing the consultant's role as a teacher. Gastroenterology 2014; 147: 1208-11.

  23. Lankenau SE, Teti M, Silva K, Bloom JJ, Harocopos A, Treese M. Patterns of Prescription Drug Misuse among Young Injection Drug Users. J Urban Health Bull N Y Acad Med 2012; 89: 1004-16.

  24. Lankenau SE, Teti M, Silva K, Bloom JJ, Harocopos A, Treese M. Initiation into Prescription Opioid Misuse among Young Injection Drug Users. Int J Drug Policy 2012; 23: 37-44.

  25. Holtzman D, Barry V, Ouellet LJ, Jarlais DCD, Vlahov D, Golub ET, Hudson SM, et al. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004. Prev Med 2009; 49: 68-73.

  26. Cheng T, Wood E, Nguyen P, Montaner J, Kerr T, DeBeck K. Crack Pipe Sharing Among Street-Involved Youth in a Canadian Setting. Drug Alcohol Rev 2015; 34: 259-66.

  27. Caiaffa WT, Zocratto KF, Osimani ML, Martínez PL, Radulich G, Latorre L, Muzzio E, et al. Hepatitis C virus among non-injecting cocaine users (NICUs) in South America: can injectors be a bridge? Addiction 2011; 106: 143-51.

  28. Porter J, Bonilla L. Crack users’ cracked lips: an additional HIV risk factor. Am J Public Health 1993; 83: 1490-1.

  29. Koblin BA, Factor SH, Wu Y, et al. Hepatitis C virus infection among noninjecting drug users in New York City. J Med Virol 2003; 70: 387-90.

  30. Scheinmann R, Hagan H, Lelutiu-Weinberger C, Stern R, Jarlais DCD, Flom PL, Strauss, S. Non-injection drug use and Hepatitis C Virus: A systematic review. Drug Alcohol Depend 2007; 89: 1-12.

  31. Aspinall EJ, Weir A, Sacks-Davis R, Spelman T, Grebely J, Higgs P, Hutchinson SJ, et al. Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study. Int J Drug Policy 2014; 25: 179-82.

  32. Harris M, Rhodes T. Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. Harm Reduct J 2013; 10: 7.

  33. Dolganiuc A. Alcohol and Viral Hepatitis. Alcohol Res Curr Rev 2015; 37: 299-309.

  34. Anderson BJ, Gogineni A, Charuvastra A, Longabaugh R, Stein MD. Adverse drinking consequences among alcohol abusing intravenous drug users. Alcohol Clin Exp Res 2001; 25: 41-5.

  35. Campbell JV, Hagan H, Latka MH, Garfein RS, Golub ET, Coady MH, Thomas DL, et al. High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities. Drug Alcohol Depend 2006; 81: 259-65.

  36. Hagan H, Latka MH, Campbell JV, Golub ET, Garfein RS, Thomas DA, Kapadia F, et al. Eligibility for Treatment of Hepatitis C Virus Infection among Young Injection Drug Users in 3 US Cities. Clin Infect Dis 2006; 42: 669-72.

  37. Takase S, Takada N, Sawada M, Tsutsumi M, Takada A. Relationship between alcoholic liver disease and HCV infection. Alcohol Alcohol Oxf Oxfs Suppl 1993; 1A: 77-84.

  38. Askgaard G, Grřnbćk M, Kjćr MS, Tjřnneland A, Tolstrup JS. Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study. J Hepatol 2015; 62: 1061-7.

  39. Zduniak K, Ziólkowski P, Regnell P, Tollet-Egnell P, Ĺkesson L, Cooper Me. Immunohistochemical analysis of cannabinoid receptor 1 expression in steatotic rat livers. Exp Ther Med 2016; 11: 1227-30.

  40. Denaës T, Lodder J, Chobert M-N, Ruiz I, Pawlotsky J-M, Lotersztajn S, Teixeira-Clerc F. The Cannabinoid Receptor 2 Protects Against Alcoholic Liver Disease Via a Macrophage Autophagy-Dependent Pathway. Sci Rep 2016; 6: 28806. Published online 2016 Jun 27.

  41. Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, Manin S, Tran-Van-Nhieu J, et al. CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol 2008; 153: 286-9.

  42. Hézode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani E-S, Pawlotsky JM, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42: 63-71.

  43. Gonzalez HC, Duarte-Rojo A. Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes. Curr Gastroenterol Rep 2016; 18: 32.

  44. Alcoholism and Psychiatric Disorders [Internet]. [cited 2016 Nov 2]. Available from: http: //pubs.niaaa.nih.gov

  45. Brady KT, Sonne SC. The relationship between substance abuse and bipolar disorder. J Clin Psychiatry 1995; 56: 19-24.

  46. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011; 44: 195-235.

  47. Smolders EJ, de Kanter CTMM, de Knegt RJ, van der Valk M, Drenth JPH, Burger DM. Drug-Drug Interactions Between Direct- Acting Antivirals and Psychoactive Medications. Clin Pharmacokinet 2016; 55: 1471-94.

  48. Deuffic-Burban S, Boursier J, Leroy V, Yazdanpanah Y, Castera L, Mathurin P. Are Targeted Treatment Recommendations in Chronic Hepatitis C Tailored to Diagnostic Methods of Fibrosis? J Hepatol 2017; 66: 304-12.

  49. Ho S, Brau N, Cheung R, Liu L, Sanchez C, Sklar M, Phelps TE, et al. Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse. Clin Gastroenterol Hepatol 2015; 13: 2005-14.

  50. Innes H, McDonald S, Hayes P, Dillon JF, Allen S, Goldberg D, Mills PR, et al. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. J Hepatol 2017; 66: 19-27.




2020     |     www.medigraphic.com